US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
This article was originally published in Scrip
Executive Summary
The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.